Novavax, Inc.

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant vaccines for infectious diseases using its virus-like particle platform (VLP) technology. It develops vaccine product candidates that target pandemic influenza, including H1N1 and H5N1 strains; seasonal influenza; and respiratory syncytial virus (RSV).

Ticker:
NVAX
Exchange:
NASDAQ (See More NASDAQ Companies)
Sector:
Healthcare (See More Healthcare Companies)